122 related articles for article (PubMed ID: 19534603)
21. Effects of long-term use of HAART on oral health status of HIV-infected subjects.
Nittayananta W; Talungchit S; Jaruratanasirikul S; Silpapojakul K; Chayakul P; Nilmanat A; Pruphetkaew N
J Oral Pathol Med; 2010 May; 39(5):397-406. PubMed ID: 20202089
[TBL] [Abstract][Full Text] [Related]
22. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
[TBL] [Abstract][Full Text] [Related]
23. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
Silveira MP; Maurer P; Guttier MC; Moreira LB
J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
[TBL] [Abstract][Full Text] [Related]
25. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
26. Long-term quality-of-life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile.
Burgoyne RW; Rourke SB; Behrens DM; Salit IE
AIDS Behav; 2004 Jun; 8(2):151-63. PubMed ID: 15187477
[TBL] [Abstract][Full Text] [Related]
27. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy.
Kauf TL; Roskell N; Shearer A; Gazzard B; Mauskopf J; Davis EA; Nimsch C
Value Health; 2008 Dec; 11(7):1144-53. PubMed ID: 18494750
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life and clinical outcomes in kidney transplant recipients.
Molnar-Varga M; Molnar MZ; Szeifert L; Kovacs AZ; Kelemen A; Becze A; Laszlo G; Szentkiralyi A; Czira ME; Mucsi I; Novak M
Am J Kidney Dis; 2011 Sep; 58(3):444-52. PubMed ID: 21658828
[TBL] [Abstract][Full Text] [Related]
29. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
30. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M
HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
[TBL] [Abstract][Full Text] [Related]
31. Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.
Locadia M; van Grieken RA; Prins JM; de Vries HJ; Sprangers MA; Nieuwkerk PT
Antivir Ther; 2006; 11(3):335-41. PubMed ID: 16759050
[TBL] [Abstract][Full Text] [Related]
32. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life of HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa.
Mekuria LA; Sprangers MA; Prins JM; Yalew AW; Nieuwkerk PT
AIDS Care; 2015; 27(8):934-45. PubMed ID: 25782603
[TBL] [Abstract][Full Text] [Related]
34. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
35. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
Manfredi R
Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
[TBL] [Abstract][Full Text] [Related]
36. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.
Lohse N; Ladefoged K; Pedersen L; Jensen-Fangel S; Sørensen HT; Obel N
Scand J Infect Dis; 2004; 36(10):738-42. PubMed ID: 15513400
[TBL] [Abstract][Full Text] [Related]
37. Antiretroviral treatment and quality of life in Africans living with HIV: 12-month follow-up in Burkina Faso.
Jaquet A; Garanet F; Balestre E; Ekouevi DK; Azani JC; Bognounou R; Dah E; Kondombo JC; Dabis F; Drabo J
J Int AIDS Soc; 2013 Dec; 16(1):18867. PubMed ID: 24369739
[TBL] [Abstract][Full Text] [Related]
38. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
Ferradini L; Jeannin A; Pinoges L; Izopet J; Odhiambo D; Mankhambo L; Karungi G; Szumilin E; Balandine S; Fedida G; Carrieri MP; Spire B; Ford N; Tassie JM; Guerin PJ; Brasher C
Lancet; 2006 Apr; 367(9519):1335-42. PubMed ID: 16631912
[TBL] [Abstract][Full Text] [Related]
39. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
